Brief: Xuanzhu Biopharmaceutical Enters Licensing Agreement With Boston Oncology
09/04/2026 09:44
April 9 (Reuters) - Xuanzhu Biopharmaceutical Co Ltd 2575.HK: XUANZHUBIO-B ENTERS LICENSING AGREEMENT WITH BOSTON ONCOLOGY FOR BIREOCICLIB AND DIROZALKIB ON APRIL 9, 2026 BOSTON ONCOLOGY GRANTED EXCLUSIVE LICENSE FOR BIREOCICLIB AND DIROZALKIB IN 21 MENA COUNTRIES GROUP TO RECEIVE PAYMENTS EXCEEDING $100 MILLION AND ROYALTIES UNDER AGREEMENT Further company coverage: 2575.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xuanzhu Biopharmaceutical
See all newsBrief: Xuanzhu Biopharmaceutical Announces Commercial Cooperation With Innobic For Birecociclib
Xuanzhu Biopharmaceutical climbs to three-week high on approval for drug clinical trial
Brief: Xuanzhu Biopharmaceutical Says Approved To Initiate Phase Iii Trial Of Anaprazole Sodium
China's Xuanzhu set for best day in 6 months on drug deal with Boston Oncology
Brief: Xuanzhu Biopharmaceutical Enters Licensing Agreement With Boston Oncology